WASp-Stabilizing Small Molecules for Immune Deficiency Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Wiskott-Aldrich Syndrome (WAS) and X-linked thrombocytopenia (XLT) are risky and ineffective, with hematopoietic stem cell transplantation carrying significant complications and gene therapy posing risks of insertional oncogenesis, while splenectomy provides only temporary relief with potential infections and complications.
Innovation Solution
Development of small molecule compounds (SMCs) that modulate the degradation of Wiskott-Aldrich Syndrome protein (WASp) by binding to its WH1 domain, protecting it from ubiquitylation and degradation, thereby upregulating its expression and restoring immune cell function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hematopoietic stem cell transplantation is performed to treat WAS, then immune function is restored, but significant complications and risks occur
Solution Approach 1:
The patent uses small molecule compounds as intermediaries to modulate WASp degradation pathways. These compounds act as mediators between the defective WASp protein and the cellular degradation machinery, preventing harmful degradation without requiring stem cell transplantation. The compounds bind to specific domains of WASp to stabilize it, thereby restoring immune function through a safer intermediate mechanism.
Solution Approach 2:
The patent replaces the mechanical/invasive procedure of stem cell transplantation with a molecular-level intervention using small molecule compounds. Instead of introducing external cells that require engraftment and carry transplantation risks, the invention uses chemically synthesized molecules to correct the underlying protein instability issue directly within the patient's own cells.
2Reliability
If gene therapy is performed to treat WAS, then WASp expression is restored, but risks of insertional oncogenesis occur
Solution Approach 1:
The patent employs small molecule compounds that are transient and do not integrate into the genome. These molecules act temporarily to stabilize WASp protein expression without permanent genetic modification, thereby avoiding the carcinogenic risks of insertional mutagenesis associated with viral vector-based gene therapy while still achieving therapeutic WASp restoration.
Solution Approach 2:
The small molecule compounds serve as intermediaries that indirectly restore WASp function without directly modifying the genome. Rather than inserting functional genes that could integrate into oncogenic locations, these molecules mediate protein stabilization through non-genomic mechanisms, eliminating the insertional oncogenesis risk while maintaining therapeutic efficacy.
3Object-affected harmful factors
If splenectomy is performed to treat WAS, then bleeding symptoms are relieved temporarily, but infections and complications occur
Solution Approach 1:
The patent enables the body's own immune system to function properly by stabilizing WASp protein levels through small molecule compounds. Instead of removing the spleen to alleviate bleeding symptoms, the invention allows the spleen and other immune organs to self-service and function normally by correcting the underlying protein instability, thereby maintaining immune defense while relieving bleeding symptoms.
Solution Approach 2:
The patent replaces the surgical mechanical intervention of splenectomy with a molecular mechanism that corrects the root cause of both bleeding and immune dysfunction. By using small molecule compounds to stabilize WASp, the treatment achieves symptom relief without compromising the spleen's protective immune functions, thereby avoiding infection risks.
4Object-affected harmful factors
If conventional treatments are used for WAS, then some symptoms are managed, but effectiveness is limited and risks are high
Solution Approach 1:
The patent changes the fundamental parameter of WASp protein stability through small molecule compound intervention. By targeting the degradation pathways and modifying protein half-life parameters, the invention achieves effective symptom management while improving treatment safety. This molecular-level parameter modification avoids the high risks associated with conventional surgical and transplantation-based approaches.
Data Source
Figure 1A~1C
Figure 2
Figure 3A~3D
AI summary
The present invention provides specific small molecule compounds that modulate degradation and stability of Wiskott-Aldrich Syndrome protein (WASp), methods and uses thereof in innate and acquired immune-related disorders or conditions, specifically, in primary and secondary immune-deficiencies.